Evidence map›Paper›PMID 25801501›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.

Lara A Ray, Spencer Bujarski, Kelly E Courtney, Nathasha R Moallem, Katy Lunny, Daniel Roche, Adam M Leventhal, Steve Shoptaw, Keith Heinzerling, Edythe D London and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Bupropion and Naltrexone in Methamphetamine Use Disorder.The New England journal of medicine · 2021
    Trial
  8. Trial
  9. The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lara A Ray1] Department of Psychology, University of California, Los Angeles, Los Angeles, CA, USA [2] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Spencer BujarskiDepartment of Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
Kelly E CourtneyDepartment of Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
Nathasha R MoallemDepartment of Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
Katy LunnyDepartment of Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
Daniel RocheDepartment of Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
Adam M LeventhalDepartments of Preventive Medicine and Psychology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Steve Shoptaw1] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA [2] Department of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Keith Heinzerling1] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA [2] Department of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Edythe D London1] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA [2] Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USNeurobehavioral Systems · USUniversity of Southern California · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Pharmacogenetics of Natlrexone for Methamphetamine Use DisorderR21DA029831 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2011 to 2013
$478k
Subjective Response and Self-Administration of Alcohol in the Human LabF31AA022569 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUJARSKI, SPENCER · 2014 to 2015
$69k
The Effects of Naltrexone on Neural Responses to Methamphetamine CuesF31DA035604 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COURTNEY, KELLY ELIZABETH · 2013 to 2014
$66k
NCATS NIH HHS UL1TR000124NCRR NIH HHS M01 RR000865NCRR NIH HHS UL1 RR033176NCRR NIH HHS UL1RR033176NIAAA NIH HHS F31 AA022569NIDA NIH HHS DA029831NIDA NIH HHS F31 DA035604NIDA NIH HHS R21 DA029831NIDA NIH HHS T32 DA024635
6 · The paper itself

Abstract

Methamphetamine (MA) use disorder is a serious psychiatric condition for which there are no FDA-approved medications. Naltrexone (NTX) is an opioid receptor antagonist with demonstrated efficacy, albeit moderate, for the treatment of alcoholism and opioid dependence. Preclinical and clinical studies suggest that NTX may be useful for the treatment of MA use disorder. To inform treatment development, we conducted a double-blind, randomized, crossover, placebo-controlled human laboratory study of NTX. Non-treatment-seeking individuals meeting DSM-IV criteria for MA abuse or dependence (n=30) completed two separate 5-day inpatient stays. During each admission, participants completed testing sessions comprised of MA cue-reactivity and intravenous MA administration (30 mg) after receiving oral NTX (50 mg) or placebo for 4 days. This study tested the hypotheses that NTX would (a) attenuate cue-induced MA craving, and (b) reduce subjective responses to MA administration. Results largely supported the study hypotheses such that (a) NTX significantly blunted cue-induced craving for MA and (b) attenuated several of the hedonic subjective effects of MA, including craving, during controlled MA administration and as compared with placebo. NTX decreased overall subjective ratings of 'crave drug,' 'stimulated,' and 'would like drug access,' decreased the the post-MA administration timecourse of 'anxious' and increased ratings of 'bad drug effects,' as compared with placebo. These findings support a potential mechanism of action by showing that NTX reduced cue-induced craving and subjective responses to MA. This is consistent with positive treatment studies of NTX for amphetamine dependence, as well as ongoing clinical trials for MA.

Indexed as

AdultAmphetamine-Related DisordersAnalysis of VarianceBlood PressureCross-Over StudiesCuesDouble-Blind MethodFemaleHeart RateHumansMaleMethamphetamineMiddle AgedNaltrexoneNarcotic AntagonistsSex CharacteristicsMethamphetamineNaltrexoneNarcotic Antagonists

Identifiers

PMID25801501
PMCPMC4538349
OpenAlexW2086573094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.